MedElevator Войти в исследования
← Поиск публикаций

DOI 10.5694/j.1326-5377.1987.tb133351.x

Медицинская библиотека · The Medical journal of Australia · 1987

Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.

Barratt P S, Toogood I R

СтатьяПеревод пока не подготовлен

Аннотация

Sensorineural hearing loss was detected in nine (33%) of 27 patients with beta-thalassaemia major. All were receiving regular hypertransfusion and nightly subcutaneous infusions of desferrioxamine. A retrospective analysis of these patients was undertaken to determine the risk factors for the development of deafness. No statistically significant differences were found between the affected and unaffected groups with respect to age, ferritin levels or lengths of time that they had received desferrioxamine, but the trends were similar to those reported by other authors. However, the desferrioxamine dosage was similar in both our groups (less than 60 mg/kg a day), and lower in the affected group than other authors have reported. Two patients experienced some resolution of their deafness when their dosage of desferrioxamine was lowered. These results suggest that the ototoxic effect of desferrioxamine is dose-related and can occur at relatively low doses of the drug.

Для цитирования: Barratt P S, Toogood I R. Hearing loss attributed to desferrioxamine in patients with beta-thalassaemia major.. The Medical journal of Australia. 1987. DOI: 10.5694/j.1326-5377.1987.tb133351.x.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.